Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOJ6E8
|
|||
| Drug Name |
AMG 596
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [2], [3] | ||
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor receptor variant III (EGFR vIII) | Target Info | Inhibitor | [4] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [4] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03296696) Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.